GlassScriptPhysician profile
Raymond Alderfer
NPI 1245294362
$2,300.27
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,632 · 2020: $468 · 2021: $186 · 2022: $13.19.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $563.58 | 2019-2021 | |
| Allergan, INC. | $419.22 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $310.67 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $259.66 | 2019-2022 | |
| Lundbeck LLC | $195.19 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $143.39 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $135.46 | 2019 | |
| Janssen Pharmaceuticals, INC | $89.74 | 2019 | |
| Shire North American Group INC | $64.11 | 2019 | |
| Ironshore Pharmaceuticals INC. | $29.89 | 2019 | |
| Neuronetics, INC. | $20.02 | 2019 | |
| Abbvie INC. | $16.05 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.36 | 2020 | |
| Amgen INC. | $13.69 | 2019 | |
| Arbor Pharmaceuticals, INC. | $13.18 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $11.06 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Alderfer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.